<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02848079</url>
  </required_header>
  <id_info>
    <org_study_id>1605017852</org_study_id>
    <nct_id>NCT02848079</nct_id>
  </id_info>
  <brief_title>TAS-OX for Refractory Metastatic Colon Cancer</brief_title>
  <official_title>TAS-102 and Oxaliplatin (TAS-OX) for Refractory Metastatic Colon Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine the safety and effectiveness of oxaliplatin in combination with&#xD;
      TAS-102 (TAS-OX) for treatment of patients with metastatic colorectal cancer whose cancer has&#xD;
      progressed or recurred after FOLFOX chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      TAS-102 is an oral agent, which consists of a combination of a novel antimetabolite&#xD;
      5-trifluorothymidine (FTD) and a thymidine phosphorylase inhibitor (TPI) that prevents&#xD;
      degradation of FTD. It has demonstrated activity in chemorefractory metastatic colorectal&#xD;
      cancer (mCRC) patients. In the Japanese randomized phase II trial, TAS-102 improved medial&#xD;
      overall survival when compared to placebo (9.0 vs.6.6 months, Hazard Ratio (HR) 0.56) in&#xD;
      patients with mCRC refractory to 5-fluorouracil (5-FU), irinotecan and oxaliplatin.&#xD;
      Subsequently, a randomized phase III study conducted in 13 countries (RECOURSE trial)&#xD;
      confirmed this benefit on overall survival when compared to placebo (7.1 months vs. 5.3&#xD;
      months, HR 0.68) in patients with refractory metastatic colorectal cancer (CRC) 5.&#xD;
&#xD;
      Oxaliplatin is a third generation platinum compound, which is active when used together with&#xD;
      5-FU in the treatment of mCRC (FOLFOX). FOLFOX chemotherapy, which is frequently combined&#xD;
      with anti-angiogenic agent Bevacizumab, is widely accepted as the preferred first-line&#xD;
      regimen in the treatment of this disease in the US. Oxaliplatin is also frequently&#xD;
      reintroduced in more advanced settings. Reintroduction is seen after progression on&#xD;
      maintenance therapy, after resolution of previous treatment limiting neuropathy, after&#xD;
      disease recurrence post adjuvant treatment or post metastasectomy. In the control arm of a&#xD;
      randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced&#xD;
      colorectal cancer (OPTIMOX1 study), oxaliplatin was reintroduced in 27% of patients. Although&#xD;
      patients derive clinical benefit when oxaliplatin is reintroduced, the response rates are not&#xD;
      as robust as during initial exposures. Decreased efficacy may be at least in part due to&#xD;
      prolonged exposure and resultant resistance to 5-FU, which is a backbone in maintenance and&#xD;
      in oxaliplatin containing regimens. Hence, the investigators propose exploring the safety and&#xD;
      efficacy of oxaliplatin in combination with an alternative anti-metabolite TAS-102 (TAS-OX).&#xD;
&#xD;
      TAS-102 has demonstrated activity in 5-FU refractory mCRC, so the investigators hypothesize&#xD;
      that TAS-OX may serve as an alternative drug combination for patients who have progressed or&#xD;
      recurred after FOLFOX, and who are candidates for additional oxaliplatin therapy.&#xD;
&#xD;
      This is a 2-part clinical trial with TAS-102 in combination with oxaliplatin. The first part&#xD;
      will be a dose-finding run-in phase and will enroll 3-18 patients. The second part, the focus&#xD;
      of this study, will be a single arm cohort , which will further evaluate the safety, as well&#xD;
      as efficacy, of TAS-OX in the treatment of mCRC. The subjects in part 2 will be treated with&#xD;
      the drug doses determined in Part 1 of the trial. Up to 50 patients will be enrolled in part&#xD;
      2. Anticipated enrollment may be as high as 68 patients. Maximum potential enrollment is&#xD;
      listed under anticipated enrollment, below.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 31, 2016</start_date>
  <completion_date type="Actual">June 2, 2020</completion_date>
  <primary_completion_date type="Actual">June 2, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>up to 30 days following discontinuation of treatment</time_frame>
    <description>Overall Response Rate was measured by Response Evaluation Criteria In Solid Tumor (RECIST) 1.1 criteria. Tumors were assessed with CT or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.&quot;.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>from the date of start of treatment to the date of first documented progression or any cause of death assessed up to 12 months.</time_frame>
    <description>Progression Free Survival was assessed according to RECIST criteria version 1.1. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>from the date of start of treatment to the date of any cause of death assessed up to 24 months.</time_frame>
    <description>Overall Survival was assessed by the time to death from start of study.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Colorectal Neoplasms</condition>
  <arm_group>
    <arm_group_label>combined TAS-102 and oxaliplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination treatment with TAS-102 and oxaliplatin. Combination treatment with TAS-102 and oxaliplatin. TAS-102 is an oral medication; oxaliplatin (TAS-OX) is given by infusion. In Part 1 treatments were started at level 1 doses, which were based on prior clinical experience with the medications studied. Dose escalation followed a traditional &quot;3+3&quot; design. The subjects in Part 2 were treated with dose level 3.&#xD;
Oxaliplatin infusion was given on day 1 of each cycle. TAS-102 was taken twice daily on days 1-5 of each cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>combined TAS-102 and TAS-OX</intervention_name>
    <description>Combination treatment with TAS-102 and oxaliplatin. TAS-102 is an oral medication; oxaliplatin (TAS-OX) is given by infusion.</description>
    <arm_group_label>combined TAS-102 and oxaliplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically confirmed stage IV colon cancer (AJCC 7th edition) that has progressed&#xD;
             after standard therapy that included 5-FU, irinotecan and oxaliplatin. Patients who&#xD;
             could not tolerate standard agents because of unacceptable, but reversible, toxicity&#xD;
             necessitating their discontinuation will be allowed to participate.&#xD;
&#xD;
          2. Patients who had received adjuvant chemotherapy and had recurrence during or within 6&#xD;
             months of completion of the adjuvant chemotherapy will be allowed to count the&#xD;
             adjuvant therapy as one chemotherapy regimen.&#xD;
&#xD;
          3. Progression of disease must be documented on the most recent scan.&#xD;
&#xD;
          4. Presence of measurable disease (not required for Phase 1 portion of the trial).&#xD;
&#xD;
          5. Retrovirus-associated DNA sequences (RAS) mutation and mismatch repair (MMR) status&#xD;
             must be determined (or tissue availability for testing if not already determined)&#xD;
&#xD;
          6. Age 18 years or older.&#xD;
&#xD;
          7. Eastern Cooperative Oncology Group (ECOG) performance status 0-1.&#xD;
&#xD;
          8. Life expectancy of at least 3 months.&#xD;
&#xD;
          9. Patient with adequate organ function:&#xD;
&#xD;
               1. Absolute neutrophil count (ANC) ≥ 1.5 x 109/L&#xD;
&#xD;
               2. Hemoglobin ≥ 9 g/dL&#xD;
&#xD;
               3. Platelets (PLT) ≥ 75 x 109/L&#xD;
&#xD;
               4. Aspartate aminotransferase (AST)/Alanine aminotransferase (ALT) ≤ 5 x Upper limit&#xD;
                  of normal (ULN)&#xD;
&#xD;
               5. Total serum bilirubin of ≤1.5 mg/dL (except for Grade 1 hyperbilirubinemia due&#xD;
                  solely to a medical diagnosis of Gilbert's syndrome).&#xD;
&#xD;
               6. Albumin ≥ 2.5 g/dL&#xD;
&#xD;
               7. Serum creatinine ≤ 1.5 x institutional ULN (Cockcroft and Gault formula)&#xD;
&#xD;
         10. Adequate contraception if applicable.&#xD;
&#xD;
         11. Women who are nursing must discontinue nursing prior to enrollment in the program.&#xD;
&#xD;
         12. Ability to take oral medication (i.e. no feeding tube).&#xD;
&#xD;
         13. Patient able and willing to comply with study procedures as per protocol.&#xD;
&#xD;
         14. Patient able to understand and willing to sign and date the written voluntary informed&#xD;
             consent form (ICF) at screening visit prior to any protocol-specific procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who have previously received TAS-102.&#xD;
&#xD;
          2. Grade 2 or higher peripheral neuropathy.&#xD;
&#xD;
          3. Symptomatic Central nervous system (CNS) metastases requiring treatment.&#xD;
&#xD;
          4. Other active malignancy within the last 3 years (except for non-melanoma skin cancer&#xD;
             or a non-invasive/in situ cancer).&#xD;
&#xD;
          5. Pregnancy or breast feeding.&#xD;
&#xD;
          6. Current therapy with other investigational agents.&#xD;
&#xD;
          7. Active infection with body temperature ≥38°C due to infection.&#xD;
&#xD;
          8. Major surgery within prior 4 weeks (the surgical incision should be fully healed prior&#xD;
             to drug administration).&#xD;
&#xD;
          9. Any anticancer therapy within prior 3 weeks of first dose of study drug.&#xD;
&#xD;
         10. History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to TAS-102.&#xD;
&#xD;
         11. Current therapy with other investigational agents or participation in another clinical&#xD;
             study or any investigational agent received within prior 4 weeks.&#xD;
&#xD;
         12. Grade 3 or higher hypersensitivity reaction to oxaliplatin, or grade 1-2&#xD;
             hypersensitivity reaction to oxaliplatin not controlled with pre-medication.&#xD;
&#xD;
         13. Unresolved toxicity of greater than or equal to Common Terminology Criteria for&#xD;
             Adverse Events (CTCAE) Grade 2 attributed to any prior therapies (excluding anemia,&#xD;
             alopecia, skin pigmentation, and platinum-induced neurotoxicity).&#xD;
&#xD;
         14. Extended field radiation within prior 4 weeks of first dose of study drug or limited&#xD;
             field radiation within prior 2 weeks of first dose of study drug.&#xD;
&#xD;
         15. Psychological, familial, or sociological condition potentially hampering compliance&#xD;
             with the study protocol and follow-up schedule.&#xD;
&#xD;
         16. Involvement in the planning and/or conduct of the study.&#xD;
&#xD;
         17. Previous enrollment in the present study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeremy S. Kortansky, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale Cancer Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>July 21, 2016</study_first_submitted>
  <study_first_submitted_qc>July 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2016</study_first_posted>
  <results_first_submitted>June 3, 2021</results_first_submitted>
  <results_first_submitted_qc>June 29, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 20, 2021</results_first_posted>
  <last_update_submitted>June 29, 2021</last_update_submitted>
  <last_update_submitted_qc>June 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 20, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/79/NCT02848079/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 21, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/79/NCT02848079/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Combined TAS-102 and TAS-OX</title>
          <description>Combination treatment with TAS-102 and oxaliplatin. TAS-102 is an oral medication; oxaliplatin (TAS-OX) is given by infusion. In Part 1 treatments were started at level 1 doses, which were based on prior clinical experience with the medications studied. Dose escalation followed a traditional &quot;3+3&quot; design. The subjects in Part 2 were treated with dose level 3.&#xD;
Oxaliplatin infusion was given on day 1 of each cycle. TAS-102 was taken twice daily on days 1-5 of each cycle.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Receieved Study Treatment</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Discontinued</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Combined TAS-102 and TAS-OX</title>
          <description>Combination treatment with TAS-102 and oxaliplatin. TAS-102 is an oral medication; oxaliplatin (TAS-OX) is given by infusion.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="41"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62" lower_limit="42" upper_limit="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ECOG</title>
          <description>Eastern Cooperative Oncology Group (ECOG) performance status is used to determine performance status.&#xD;
A score of &quot;0&quot; is defined as - Fully active, able to carry on all pre-disease performance without restriction A score of &quot;1&quot; is defined as - Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Location of primary tumor, No.</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Left side of colon, including rectum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right side of colon</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Stage at diagnosis</title>
          <description>Stage at diagnosis was assessed using AJCC version 7. The lower the number, the less the cancer has spread.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Histology</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Well-differentiated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderately differentiated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poorly differentiated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>High microsatellite instability</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>KRAS/BRAF mutation</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>KRAS mutation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BRAF mutation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wild type</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of prior therapies</title>
          <description>The number of prior therapies a patient had received at baseline assessment.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>1 therapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 therapies</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 therapies</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 4 therapies</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Progression during prior oxaliplatin</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Response Rate</title>
        <description>Overall Response Rate was measured by Response Evaluation Criteria In Solid Tumor (RECIST) 1.1 criteria. Tumors were assessed with CT or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.&quot;.</description>
        <time_frame>up to 30 days following discontinuation of treatment</time_frame>
        <population>Intention-to-treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Combined TAS-102 and TAS-OX</title>
            <description>Combination treatment with TAS-102 and oxaliplatin. TAS-102 is an oral medication; oxaliplatin (TAS-OX) is given by infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate</title>
          <description>Overall Response Rate was measured by Response Evaluation Criteria In Solid Tumor (RECIST) 1.1 criteria. Tumors were assessed with CT or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.&quot;.</description>
          <population>Intention-to-treat (ITT)</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" lower_limit="0" upper_limit="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression Free Survival</title>
        <description>Progression Free Survival was assessed according to RECIST criteria version 1.1. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.</description>
        <time_frame>from the date of start of treatment to the date of first documented progression or any cause of death assessed up to 12 months.</time_frame>
        <population>Intention-to-treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Combined TAS-102 and TAS-OX</title>
            <description>Combination treatment with TAS-102 and oxaliplatin. TAS-102 is an oral medication; oxaliplatin (TAS-OX) is given by infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival</title>
          <description>Progression Free Survival was assessed according to RECIST criteria version 1.1. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.</description>
          <population>Intention-to-treat (ITT)</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" lower_limit="2.4" upper_limit="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Overall Survival was assessed by the time to death from start of study.</description>
        <time_frame>from the date of start of treatment to the date of any cause of death assessed up to 24 months.</time_frame>
        <population>Intention-to-Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Combined TAS-102 and TAS-OX</title>
            <description>Combination treatment with TAS-102 and oxaliplatin. TAS-102 is an oral medication; oxaliplatin (TAS-OX) is given by infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Overall Survival was assessed by the time to death from start of study.</description>
          <population>Intention-to-Treat (ITT)</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8" lower_limit="5.4" upper_limit="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>up to 38 months</time_frame>
      <desc>The reported AEs here are all AEs in the study, regardless of attribution. Whereas in the published manuscript, SAE's were reported when they could be attributed to treatment and that a 10% threshold was used in reporting AE's.</desc>
      <group_list>
        <group group_id="E1">
          <title>Combined TAS-102 and TAS-OX</title>
          <description>Combination treatment with TAS-102 and oxaliplatin. TAS-102 is an oral medication; oxaliplatin (TAS-OX) is given by infusion.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Ascites</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>General disorders and administration site conditions - Other, specify</sub_title>
                <description>Failure to thrive</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatobiliary disorders - Other, specify</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Intrahepatic biliary ductal dilation</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and infestations - Other, specify</sub_title>
                <description>Perirectal abcess</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal and urinary disorders - Other, specify</sub_title>
                <description>Hydroureteronephrosis</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders - Other, specify</sub_title>
                <description>Post-influenza pneumonia</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thromboembolic event</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="46" subjects_affected="25" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Platelet count decrease</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="28" subjects_affected="20" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Blood and lymphatic system disorders - Other, specify</sub_title>
                <counts group_id="E1" events="24" subjects_affected="8" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="20" subjects_affected="12" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="14" subjects_affected="11" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="19" subjects_affected="11" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="24" subjects_affected="13" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="39" subjects_affected="22" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="21" subjects_affected="16" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="48" subjects_affected="27" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Neutrophil count decrease</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="49" subjects_affected="15" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="51" subjects_affected="14" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="12" subjects_affected="9" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="22" subjects_affected="14" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="22" subjects_affected="10" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>INR increased</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="11" subjects_affected="4" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="49" subjects_affected="15" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="59" subjects_affected="17" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Weight Loss</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="17" subjects_affected="11" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="17" subjects_affected="12" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Paresthesia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="8" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="24" subjects_affected="17" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="12" subjects_affected="9" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders - Other, specify</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="23" subjects_affected="12" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Jeremy Kortmansky</name_or_title>
      <organization>Yale University</organization>
      <phone>1 (203) 407-8002</phone>
      <email>jeremy.kortmansky@yale.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

